Study Details

General Information

Akros Diabetes 004

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi- Center, Parallel Group Study Evaluating the Efficacy, Safety and Pharmacokinetics of (study drug) Administered for 12 Weeks in Untreated or Metformin-treated Type 2 Diabetic Patients

Protocol
IdentifierAT654-U09-004
UIDb90da55e-765d-4a83-b836-df9404f2abfe
StatusDone - Archived
Phase2
CategoryDiabetes Type 2 / Adult
Launch Year2009
NCT Number-
Created2010-05-21 16:00
Last Updated2010-05-21 16:00

Description

No description provided.

Comment

No comment.

Target Dates

NameDateRequired
Enrollment ClosedNo
Enrollment OpenNo
First Patient First VisitNo
Site Initiation Mtg.2009-11-19No
PI Meeting StartNo
PI Meeting EndNo
PI Meeting ArrivalNo
PI Meeting DepartureNo
Closeout Date2010-02-24No
Final PatientVisitNo
PreStudy Selection VisitNo
Target Date 12No
Target Date 13No
Target Date 14No

Leadership

RoleStaffLoginRequired
PrincipalUnger, JeffreyJUngerNo
Recruiter-No
CoordinatorVillegas, ClaudiaCVillegasNo
RegulatoryAguirre, SandraSAguirreNo

Custom Fields

No custom fields.

Sponsor & Organization

SponsorAkros Pharma Inc.
DivisionAkros Pharma Inc.
TeamAkros Pharma Inc.
Managing SiteCatalina Research Institute, LLC
Organization

Contacts

IRB Ref
CRO
CRO Ref
Correspondence0

Opportunity

Probability0
Comment
Status ColorGainsboro
Currency-
Mayra Sibley

2 Hours

Hi there, I'm Jesse and you?
You

3 minutes

My name is Anne Clarc.
Mayra Sibley

40 seconds

Nice to meet you Anne.
How can i help you?